• Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    23 hours ago

  • Allegro inaugrates new lab at Bluechem

    1 day ago

  • eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A

    1 day ago

  • Biocair opens new office in South Africa, a clinical research hub

    Wednesday July 21st 2021

  • Bone Therapeutics provides update on the progress of clinical studies

    Monday July 19th 2021

  • Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

    Thursday July 15th 2021

  • ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

    Thursday July 15th 2021

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021

  • Your news here?

  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Thursday July 15th 2021

  • eTheRNA immunotherapies and Ghent University announce mRNA Delivery Collaboration and License Agreement

    Tuesday July 13th 2021

  • Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

    Monday July 12th 2021

Strategic Partners